Gm Csf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The safety and tolerability of GM-CSF treatment and its effects on behavior and brain pathology were studied in a mouse model of Down syndrome.

email article Treatment with the investigational monoclonal antibody mavrilimumab significantly improved outcomes among patients with severe COVID-19 also given standard of care treatment, an international phase II randomized trial found. Among patients who were not on mechanical ventilation at the time of study enrollment, but had severe COVID-19 with hyperinflammation, those given one of two doses of mavrilimumab had a 65% lower risk of mechanical ventilation or death by day 29, reported Lara Pupim, MD, of Kiniksa Pharmaceuticals in Lexington, Massachusetts. Compared with patients giv...

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital will present frontline data for DANYELZA and GM-CSF for consolidation of high-risk neuroblastoma (“HR-NB”) patients in complete re

Routine steroids save lives but suppress the entire immune system.